RxDoctor Payments Data

Daniel Brancheau, DO

Cardiovascular Disease · Grand Blanc, MINPI 1710146725

Payments from drug & device makers

$133,318in general payments, 2019–2025

Across 886 payments — averaging $150.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$92K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$20K
  • Abbott$8K
  • Abiomed$5K
  • Novartis$975
  • Johnson & Johnson$843
  • plus $7K from 47 others

What the payments were for

  • Consulting fees$3,0007%
  • Speaking & faculty fees$19,50047%
  • Travel & lodging$4081%
  • Food & beverage$18,34244%
  • Education$4161%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$133,318 in reported general payments places this provider in the 90th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$208,166
Medicare patients
558
Services billed
2,307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban302$352,625
XareltoRivaroxaban164$217,609
EntrestoSacubitril/Valsartan96$105,451
Repatha SureclickEvolocumab95$96,294
JardianceEmpagliflozin44$46,733
BrilintaTicagrelor34$27,859
Praluent PenAlirocumab23$20,999
FarxigaDapagliflozin Propanediol14$18,668
Atorvastatin Calcium236$4,516
Ranolazine ErRanolazine31$4,235
Metoprolol Succinate239$3,769
Rosuvastatin Calcium128$3,654
ClopidogrelClopidogrel Bisulfate142$2,647
Flecainide Acetate49$2,440
Amiodarone Hcl61$2,385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$662$352,625302 claims
Johnson & JohnsonXarelto$843$217,609164 claims
NovartisEntresto$975$105,45196 claims
Boehringer IngelheimJardiance$232$46,73344 claims
AstraZenecaBrilinta, Farxiga$338$46,52748 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Grand Blanc

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →